Business Description
e-Therapeutics PLC
NAICS : 325412
ISIN : GB00B2823H99
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 276.06 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 16.74 | |||||
Beneish M-Score | -2 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | -19.3 | |||||
3-Year EPS without NRI Growth Rate | -18.6 | |||||
3-Year FCF Growth Rate | -23.3 | |||||
3-Year Book Growth Rate | 49.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.96 | |||||
9-Day RSI | 37.11 | |||||
14-Day RSI | 38.11 | |||||
6-1 Month Momentum % | 0.22 | |||||
12-1 Month Momentum % | -7.23 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 22.2 | |||||
Quick Ratio | 22.2 | |||||
Cash Ratio | 19.47 | |||||
Days Sales Outstanding | 263.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.3 | |||||
Shareholder Yield % | -24.82 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -3721.77 | |||||
Net Margin % | -2957.65 | |||||
FCF Margin % | -3040.59 | |||||
ROE % | -35.52 | |||||
ROA % | -33.9 | |||||
ROIC % | -394.21 | |||||
ROC (Joel Greenblatt) % | -548.47 | |||||
ROCE % | -41.87 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 90 | |||||
PB Ratio | 1.91 | |||||
Price-to-Tangible-Book | 1.8 | |||||
EV-to-EBIT | -2.35 | |||||
EV-to-EBITDA | -2.45 | |||||
EV-to-Revenue | 81.87 | |||||
EV-to-FCF | -2.69 | |||||
Price-to-Net-Current-Asset-Value | 1.8 | |||||
Price-to-Net-Cash | 2.25 | |||||
Earnings Yield (Greenblatt) % | -42.55 | |||||
FCF Yield % | -19.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
e-Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 0.34 | ||
EPS (TTM) (£) | -0.018 | ||
Beta | -0.19 | ||
Volatility % | 145.43 | ||
14-Day RSI | 38.11 | ||
14-Day ATR (£) | 0.01244 | ||
20-Day SMA (£) | 0.099775 | ||
12-1 Month Momentum % | -7.23 | ||
52-Week Range (£) | 0.08 - 0.24 | ||
Shares Outstanding (Mil) | 584.34 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
e-Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
e-Therapeutics PLC Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
e-Therapeutics PLC Frequently Asked Questions
What is e-Therapeutics PLC(LSE:ETX)'s stock price today?
When is next earnings date of e-Therapeutics PLC(LSE:ETX)?
Does e-Therapeutics PLC(LSE:ETX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |